FONT-SIZE Plus   Neg

Novartis: Xolair Confirms Re-treatment Efficacy In CSU Patients

Novartis (NVS) announced new data showing almost 90% of chronic spontaneous urticaria or CSU patients who responded well to initial Xolair (omalizumab) treatment regained symptom control within 12 weeks of Xolair retreatment following a treatment interruption, based on Weekly Urticaria Activity Score (UAS7) criteria.

The OPTIMA Phase IIIb data re-confirmed that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled. Xolair is a targeted therapy that binds to immunoglobulin E or IgE.

CSU is a distressing skin condition that appears spontaneously and causes persistent hives and/or painful deeper swelling of the skin for 6 weeks or more. As per international treatment guidelines, the goal of treatment for CSU is the complete elimination of symptoms.

Novartis noted that Xolair can reduce or eliminate symptoms for CSU patients who have not successfully controlled their symptoms with H1 antihistamine (H1-antagonists) treatment.

Xolair is the first and only approved therapy for CSU patients who show an inadequate response to H1 antihistamines.

The company noted that findings were presented at the 26th European Academy of Dermatology and Venereology Congress in Geneva, Switzerland.

Vas Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis, said, "CSU can have a severe impact on quality of life. Its unpredictable nature, combined with the fact that some physicians mistakenly dismiss it as a trivial condition, can mean patients do not get adequate treatment with effective and long-term symptoms control. If for some reason treatment has been interrupted, these data give patients and physicians confidence that it's possible to regain effective symptom control with Xolair."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
French real estate company Unibail-Rodamco SE Tuesday announced that it has entered into an agreement to acquire Australian shopping centre group Westfield Corp. in a deal that implies an enterprise value of $24.7 billion. The deal is expected to create the world's premier developer and operator of flagship shopping destinations with 61.1 billion euros or $72.2 billion of Gross Market Value. Aerospace and defense major Boeing's shares increased in the extended trading on Monday after the company announced a 20 percent increase in quarterly dividend and also boosted its share repurchase program to $18 billion, citing its strong and growing cash flow. Checkout the companies that are expected to release quarterly financial results on Tuesday, December 12, 2017. * ARWR to benefit from collaboration agreement with Amgen * Demand for PoS software, PaaS technologies to propel PAY Q4
comments powered by Disqus
Follow RTT